ACCESS Newswire
22 Sep 2022, 18:02 GMT+10
Jaguar CEO Lisa Conte Will Also Participate in an Orphan Drug Panel Presentation on September 28th During the Lytham Partners Fall 2022 Investor Conference
SAN FRANCISCO, CA / ACCESSWIRE / September 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today announced that on September 28, 2022 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Fall 2022 Investor Conference in addition to participating in a panel presentation titled 'Orphan Drugs: Innovative Companies Addressing Rare Diseases' at the conference. Additionally, Conte will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022.
'I was so pleased to be invited to speak at the orphan drug panel at Lytham Partners' conference,' Conte said. 'Jaguar believes the clinical progress related to our target orphan indications of short bowel syndrome (SBS) and congenital diarrheal diseases (CDD) could be transformational in terms of value creation and recognition for the Company in the next approximately six months. Orphan drugs accounted for 52 percent of the total 50 novel drugs approved by the FDA's Center for Drug Evaluation and Research in 2021,1 and, according to a report from Research and Markets, the global orphan drugs market is expected to reach $229.71 billion in 2026.2 The pursuit of potential rare disease indications for the novel mechanism of action of our crofelemer drug product has become a strategic focus for Jaguar and Napo Therapeutics, the rare disease-focused company Jaguar established in 2021. Jaguar is the majority shareholder of this Italy-based company, and Napo Therapeutics holds an exclusive license to crofelemer in Europe. Our rare diseases focus complements the expected completion in the first half of 2023 of enrollment in our pivotal OnTarget trial for cancer therapy-related diarrhea (CTD). We believe this Phase 3 trial for our planned lead follow-on indication for crofelemer will also provide transformative value to Jaguar.'
Company Presentations:
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that on September 28, 2022 Company management will present at the Lytham Partners Fall 2022 Investor Conference and participate in an Orphan Drug Panel Presentation at the event, Jaguar's expectation that Company management will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, the Company's belief that the clinical progress related to the Company's target orphan indications of SBS and CDD could be transformational in terms of value creation and recognition for the Company in the next approximately six months, the third-party projection that the global orphan drugs market may reach $229.71 billion in 2026, the Company's expectation that its rare diseases focus complements the expected completion in the first half of 2023 of enrollment in the Company's OnTarget trial, and the Company's belief that the Phase 3 OnTarget trial will also provide transformative value to Jaguar. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 https://globalgenes.org/2022/01/12/a-group-of-innovative-orphan-drugs-win-fda-approval-in-2021/
2 https://www.researchandmarkets.com/reports/5553689/orphan-drugs-global-market-report-2022-by
Contact:
Peter Hodge
Jaguar Health, Inc.
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Get a daily dose of Vancouver Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Vancouver Star.
More InformationMANILA, Philippines - In a dramatic move, the International Criminal Court on Tuesday arrested the former president of the Philippines,...
BRUSSELS, Belgium: The United States has withdrawn from the board of a U.N. climate fund designed to help poor countries deal with...
NEW YORK CITY, New York - A student of Columbia University, arrested for protesting against the carnage in Gaza, has been moved out...
LOS ANGELES, California: Los Angeles County, Pasadena, and other public agencies have sued Edison International and its subsidiary,...
WASHINGTON, D.C.: According to a report in the Wall Street Journal, former President Donald Trump is planning to sign an order to shut...
Already under siege, the heavily-blockaded Gaza Strip, housing more than two million displaced people, as well as the remaining Israeli...
BENTONVILLE, Arkansas: Walmart is pressuring some Chinese suppliers to cut prices in response to President Donald Trump's imposed U.S....
NEW DELHI, India: The United States is pressing India to lower tariffs and increase defense purchases to secure a stronger bilateral...
NEW YORK, New York - U.S. stocks plunged on Monday, joining a global rout which followed U.S. President Donald Trump not ruling out...
NEW YORK CITY, New York - The global foreign exchange market experienced notable shifts on Monday, influenced by escalating trade tensions...
WASHINGTON, D.C.: The U.S. Energy Department estimates it will take US$20 billion and several years to refill the Strategic Petroleum...
LONDON, U.K.: British Petroleum CEO Murray Auchincloss saw his pay package drop to 5.4 million pounds (US$6.95 million) in 2024, down...